Compare NBR & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBR | VIR |
|---|---|---|
| Founded | 1952 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.4M | 825.0M |
| IPO Year | N/A | 2019 |
| Metric | NBR | VIR |
|---|---|---|
| Price | $52.68 | $6.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $50.75 | $25.73 |
| AVG Volume (30 Days) | 389.3K | ★ 2.2M |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 14.43 | N/A |
| Revenue | ★ $3,116,983,000.00 | $16,860,000.00 |
| Revenue This Year | $9.62 | N/A |
| Revenue Next Year | $0.84 | $48.05 |
| P/E Ratio | $3.60 | ★ N/A |
| Revenue Growth | ★ 6.52 | N/A |
| 52 Week Low | $23.27 | $4.16 |
| 52 Week High | $69.20 | $14.45 |
| Indicator | NBR | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 46.90 |
| Support Level | $49.00 | $5.73 |
| Resistance Level | $53.74 | $6.11 |
| Average True Range (ATR) | 2.81 | 0.43 |
| MACD | -0.56 | -0.10 |
| Stochastic Oscillator | 37.50 | 19.17 |
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.